Oligomeric proanthocyanidins (OPCs) from grape seed extract suppress the activity of ABC transporters in overcoming chemoresistance in colorectal cancer cells
Open accessThe DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Abstract
Multidrug resistance is a major hindrance in managing cancer. By performing a series of experiments in chemoresistant colorectal cancer cell lines, we demonstrate that oligomeric proanthocyanidins (OPCs) from grape seed extracts can sensitize both acquired (HCT116-FOr cells) and innately chemoresistant (H716 cells) cancer cells to chemotherapeutic drugs, 5-fluorouracil (5FU) and oxaliplatin, by inhibiting adenosine triphosphate-binding cassette (ABC) transporter proteins. When combined with chemotherapeutic drugs, OPCs significantly inhibited growth of the chemoresistant cells (P < 0.05 to < 0.001) and decreased the expression of several key ABC transporters. Moreover, the activity of the ABC transporters was also significantly decreased by OPCs in the cell lines (P < 0.05). We further confirmed that co-treatment with OPCs sensitized the chemoresistant cells to 5FU and oxaliplatin, as observed by improvement in cell cycle arrest, double-strand breaks and p53 accumulation in these cells. In addition, we confirmed that co-administration of OPCs with chemotherapeutic drugs significantly decreased chemoresistant xenograft tumor growth in mice (P < 0.05). Together, our study illuminates the downregulation of multiple ABC transporters as a mechanism by which OPCs overcome chemoresistance in cancer cells and may serve as adjunctive treatments in patients with refractory colorectal cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While various ABC transporter inhibitors have been shown to sensitize drug-resistant colon cancer cells to chemotherapy drugs in experimental models [98,99,100,101], the development of PGP as a therapeutic target for cancer in general has not been successful clinically [42].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [100]
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
HISAT: a fast spliced aligner with low memory requirements
Kim, D., Langmead, B., & Salzberg, S. L. (2015) · Nature Methods · doi:10.1038/nmeth.3317 · Cited by 24,112 · cited 2×
“GRCh38 downloaded from GENCODE (28) using HISAT2 (29) to generate alignment files in bam format.”
MethodHTSeq—a Python framework to work with high-throughput sequencing data
Anders, S., Pyl, P. T., & Huber, W. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu638 · Cited by 21,464
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
GENCODE: The reference human genome annotation for The ENCODE Project
Harrow, J., Frankish, A., Gonzalez, J. M., Tapanari, E., Diekhans, M., Kokocinski, F., Aken, B. L., Barrell, D., Zadissa, A., Searle, S., et al. (2012) · Genome Research · doi:10.1101/gr.135350.111 · Cited by 4,585 · cited 2×
“GRCh38 downloaded from GENCODE (28) using HISAT2 (29) to generate alignment files in bam format.”
MethodParticipation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 4,252
Revisiting the role of ABC transporters in multidrug-resistant cancer
Robey, R. W., Pluchino, K. M., Hall, M. D., Fojo, A. T., Bates, S. E., & Gottesman, M. M. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0005-8 · Cited by 1,866
P-glycoprotein: from genomics to mechanism
Ambudkar, S. V., Kimchi-Sarfaty, C., Sauna, Z. E., & Gottesman, M. M. (2003) · Oncogene · doi:10.1038/sj.onc.1206948 · Cited by 1,074
Bioactive Compounds and Antioxidant Activity in Different Types of Berries
Skrovankova, S., Sumczynski, D., Mlcek, J., Jurikova, T., & Sochor, J. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161024673 · Cited by 1,006
Edible berries: Bioactive components and their effect on human health
Nile, S. H., & Park, S. W. (2014) · Nutrition · doi:10.1016/j.nut.2013.04.007 · Cited by 886
Mechanisms of chemoresistance in cancer stem cells
Abdullah, L. N., & Chow, E. K. (2013) · Clinical and Translational Medicine · doi:10.1186/2001-1326-2-3 · Cited by 721 · cited 1×
“As ABC transporters play a central role in the development of drug resistance in cancer (9,10), we postulated that OPCs could potentially inhibit otherwise an overactive ABC transporter pathway in cancer cells, thereby offering additional insights on ways to overcoming chemoresistance in cancer.”
BackgroundFLEXBAR—Flexible Barcode and Adapter Processing for Next-Generation Sequencing Platforms
Dodt, M., Roehr, J., Ahmed, R., & Dieterich, C. (2012) · Biology · doi:10.3390/biology1030895 · Cited by 719 · cited 1×
“of RNA sequencing, Fastq files were trimmed using Flexbar to remove 3′ bases with quality scores lower than 30 before alignment, as described previously (27).”
MethodRole of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update
Mao, Q., & Unadkat, J. D. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9668-6 · Cited by 670
Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis.
Lowe, S. W., & Ruley, H. E. (1993) · Genes & Development · doi:10.1101/gad.7.4.535 · Cited by 666
Mechanisms and insights into drug resistance in cancer
Zahreddine, H., & Borden, K. L. B. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00028 · Cited by 660 · cited 1×
“As ABC transporters play a central role in the development of drug resistance in cancer (9,10), we postulated that OPCs could potentially inhibit otherwise an overactive ABC transporter pathway in cancer cells, thereby offering additional insights on ways to overcoming chemoresistance in cancer.”
BackgroundThe Role of ABC Transporters in Drug Resistance, Metabolism and Toxicity
Glavinas, H., Krajcsi, P., Cserepes, J., & Sarkadi, B. (2004) · Current Drug Delivery · doi:10.2174/1567201043480036 · Cited by 558
Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients.
Ozols, R. F., Cunnion, R. E., Klecker, R. W., Hamilton, T. C., Ostchega, Y., Parrillo, J. E., & Young, R. C. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.4.641 · Cited by 426 · cited 1×
“Consequently, various inhibitors of ABC transporters, including verapamil and quinine, were developed, which initially showed promise but failed clinically, due to high toxicity and other undesirable side effects (18,19).”
BackgroundBaer, M. R., George, S. L., Dodge, R. K., O'Loughlin, K. L., Minderman, H., Caligiuri, M. A., Anastasi, J., Powell, B. L., Kolitz, J. E., Schiffer, C. A., et al. (2002) · Blood · doi:10.1182/blood.v100.4.1224.h81602001224_1224_1232 · Cited by 366
Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer
MODOK, S., MELLOR, H., & CALLAGHAN, R. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.01.009 · Cited by 242
An Update on Overcoming MDR1-Mediated Multidrug Resistance in Cancer Chemotherapy
Takara, K., Sakaeda, T., & Okumura, K. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206775201965 · Cited by 236
Clinical trials of p-glycoprotein reversal in solid tumours
Ferry, D. R., Traunecker, H., & Kerr, D. J. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00091-3 · Cited by 214 · cited 1×
“Consequently, various inhibitors of ABC transporters, including verapamil and quinine, were developed, which initially showed promise but failed clinically, due to high toxicity and other undesirable side effects (18,19).”
BackgroundThe role of multidrug transporters in drug availability, metabolism and toxicity
Bodó, A., Bakos, É., Szeri, F., Váradi, A., & Sarkadi, B. (2003) · Toxicology Letters · doi:10.1016/s0378-4274(02)00497-6 · Cited by 214 · cited 1×
“Interestingly, the expression of MRP2, a gene notoriously connected with multidrug resistance in gastrointestinal (38), liver (39), ovarian (40–42) and several other cancers (43), increased in response to treatment with 5FU or oxaliplatin in both the chemoresistant cell lines (Figure 2C, top), but was decreased when c…”
BackgroundKönig, J., Hartel, M., Nies, A. T., Martignoni, M. E., Guo, J., Büchler, M. W., Friess, H., & Keppler, D. (2005) · International Journal of Cancer · doi:10.1002/ijc.20831 · Cited by 194
The role of ABC transporters in ovarian cancer progression and chemoresistance
Ween, M. P., Armstrong, M. A., Oehler, M. K., & Ricciardelli, C. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.05.012 · Cited by 181
Apical/Basolateral Surface Expression of Drug Transporters and its Role in Vectorial Drug Transport
Ito, K., Suzuki, H., Horie, T., & Sugiyama, Y. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-6810-2 · Cited by 174
Kelly, R. J., Draper, D., Chen, C. C., Robey, R. W., Figg, W. D., Piekarz, R. L., Chen, X., Gardner, E. R., Balis, F. M., Venkatesan, A. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1725 · Cited by 172
Grape Seed Extract Inhibits In vitro and In vivo Growth of Human Colorectal Carcinoma Cells
Kaur, M., Singh, R. P., Gu, M., Agarwal, R., & Agarwal, C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1465 · Cited by 164
ABC transporters catalyzing carbohydrate uptake
Schneider, E. (2001) · Research in Microbiology · doi:10.1016/s0923-2508(01)01201-3 · Cited by 160
Sandler, A., Gordon, M., de Alwis, D. P., Pouliquen, I., Green, L., Marder, P., Chaudhary, A., Fife, K., Battiato, L., Sweeney, C., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0644 · Cited by 151
Friedenberg, W. R., Rue, M., Blood, E. A., Dalton, W. S., Shustik, C., Larson, R. A., Sonneveld, P., & Greipp, P. R. (2006) · Cancer · doi:10.1002/cncr.21666 · Cited by 146
Berger, W., Setinek, U., Hollaus, P. H., Zidek, T., Steiner, E., Elbling, L., Cantonati, H., Attems, J., Gsur, A., & Micksche, M. (2005) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0653-9 · Cited by 142
Cancer cell adaptation to chemotherapy
Di Nicolantonio, F., Mercer, S. J., Knight, L. A., Gabriel, F. G., Whitehouse, P. A., Sharma, S., Fernando, A., Glaysher, S., Di Palma, S., Johnson, P., et al. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-78 · Cited by 133
Yamasaki, M., Makino, T., Masuzawa, T., Kurokawa, Y., Miyata, H., Takiguchi, S., Nakajima, K., Fujiwara, Y., Matsuura, N., Mori, M., et al. (2011) · British Journal of Cancer · doi:10.1038/sj.bjc.6606071 · Cited by 130
Durmus, S., Sparidans, R. W., Wagenaar, E., Beijnen, J. H., & Schinkel, A. H. (2012) · Molecular Pharmaceutics · doi:10.1021/mp3003144 · Cited by 125 · cited 1×
“Studies have elegantly shown that blocking the activity of just two transporters, ABCG2 and MDR1, increased drug accumulation by 43-fold compared to knocking down either of these transporters individually (54).”
BackgroundMembrane Transporters in Drug Development
Keogh, J. P. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-398339-8.00001-x · Cited by 121 · cited 1×
“ABC transporter activity is a crucial consideration when designing drugs as they greatly affect the pharmacokinetics and efficacy of all drugs, especially anticancer chemotherapeutic drugs (53).”
BackgroundLiu, S., Chen, S., Yuan, W., Wang, H., Chen, K., Li, D., & Li, D. (2017) · Oncotarget · doi:10.18632/oncotarget.21914 · Cited by 121
Investigational ABC transporter inhibitors
Falasca, M., & Linton, K. J. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.679339 · Cited by 120
Activities of Tannins – from in Vitro Studies to Clinical Trials
Sieniawska, E. (2015) · Natural Product Communications · doi:10.1177/1934578x1501001118 · Cited by 112
Seiden, M. V., Swenerton, K. D., Matulonis, U. A., Campos, S., Rose, P. G., Batist, G., Ette, E., Garg, V., Fuller, A., Harding, M. W., et al. (2002) · Gynecologic Oncology · doi:10.1006/gyno.2002.6762 · Cited by 98
Rotter, V., Abutbul, H., & Ben‐Ze'ev, A. (1983) · The EMBO Journal · doi:10.1002/j.1460-2075.1983.tb01543.x · Cited by 94
Gandhi, L., Harding, M. W., Neubauer, M., Langer, C. J., Moore, M., Ross, H. J., Johnson, B. E., & Lynch, T. J. (2007) · Cancer · doi:10.1002/cncr.22492 · Cited by 90
Critical Role of the Human ATP-Binding Cassette G1 Transporter in Cardiometabolic Diseases
Hardy, L. M., Frisdal, É., & Goff, W. L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091892 · Cited by 90
Toden, S., Ravindranathan, P., Gu, J., Cardenas, J., Yuchang, M., & Goel, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-21478-8 · Cited by 89 · cited 1×
“Cell proliferation was measured in cells treated with a combination of OPCs (100 ng/μl), which was the most effective dose that was previously determined in these cell lines (7,8,26); and 5FU (10 μM) or oxaliplatin (5 μM) for 72 h using water-soluble tetrazolium-1 assay (a colorimetric cell proliferation assay, from S…”
MethodSelf-citationRavindranathan, P., Pasham, D., Balaji, U., Cardenas, J., Gu, J., Toden, S., & Goel, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-32267-8 · Cited by 75 · cited 2×
“Cell proliferation was measured in cells treated with a combination of OPCs (100 ng/μl), which was the most effective dose that was previously determined in these cell lines (7,8,26); and 5FU (10 μM) or oxaliplatin (5 μM) for 72 h using water-soluble tetrazolium-1 assay (a colorimetric cell proliferation assay, from S…”
MethodSelf-citationMultidrug resistance protein in recurrent breast cancer
Nooter, K., de la Rivière, G. B., Klijn, J. G. M., Stoter, G., & Foekens, J. A. (1997) · The Lancet · doi:10.1016/s0140-6736(05)63876-7 · Cited by 65
Ravindranathan, P., Pasham, D., Balaji, U., Cardenas, J., Gu, J., Toden, S., & Goel, A. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy034 · Cited by 54 · cited 2×
“Cell proliferation was measured in cells treated with a combination of OPCs (100 ng/μl), which was the most effective dose that was previously determined in these cell lines (7,8,26); and 5FU (10 μM) or oxaliplatin (5 μM) for 72 h using water-soluble tetrazolium-1 assay (a colorimetric cell proliferation assay, from S…”
MethodSelf-citationLuo, Q., Wu, X., Zhang, Y., Shu, T., Ding, F., Chen, H., Zhao, P., Chang, W., Zhu, X., & Liu, Z. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.04.013 · Cited by 50
An Overview of Cancer Chemopreventive Potential and Safety of Proanthocyanidins
Ouédraogo, M., Charles, C., Ouédraogo, M., Guissou, I. P., Stévigny, C., & Duez, P. (2011) · Nutrition and Cancer · doi:10.1080/01635581.2011.607549 · Cited by 49
Gollücke, A. P. B., Aguiar, O., Barbisan, L. F., & Ribeiro, D. A. (2013) · Journal of Medicinal Food · doi:10.1089/jmf.2012.0170 · Cited by 45
Zhang, K., Li, M., Huang, H., Li, L., Yang, J., Feng, L., Gou, J., Jiang, M., Peng, L., Chen, L., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23253 · Cited by 30 · cited 1×
“Interestingly, the expression of MRP2, a gene notoriously connected with multidrug resistance in gastrointestinal (38), liver (39), ovarian (40–42) and several other cancers (43), increased in response to treatment with 5FU or oxaliplatin in both the chemoresistant cell lines (Figure 2C, top), but was decreased when c…”
BackgroundHerráez, E., Sanchez‐Vicente, L., Macı́as, R. I. R., Briz, Ó., & Marı́n, J. J. G. (2017) · Oncotarget · doi:10.18632/oncotarget.16119 · Cited by 17
Kamata, S., Kishimoto, T., Kobayashi, S. S., & Miyazaki, M. (2008) · Histopathology · doi:10.1111/j.1365-2559.2008.03026.x · Cited by 16 · cited 1×
“Interestingly, the expression of MRP2, a gene notoriously connected with multidrug resistance in gastrointestinal (38), liver (39), ovarian (40–42) and several other cancers (43), increased in response to treatment with 5FU or oxaliplatin in both the chemoresistant cell lines (Figure 2C, top), but was decreased when c…”
Background
Cited by
Bioactive Compounds, Health Benefits and Food Applications of Grape
Zhou, D.-D., Li, J., Xiong, R.-G., Saimaiti, A., Huang, S.-Y., Wu, S.-X., Yang, Z.-J., Shang, A., Zhao, C.-N., Gan, R.-Y., et al. (2022) · Foods · doi:10.3390/foods11182755 · Cited by 206
“In vitro and in vivo Acquired and innately chemo-resistant colorectal cancer cells (HCT116-FOr cells and H716 cells); HCT116-FOr xenograft mice Oligomeric proanthocyanidins from grape seed extract Culture: 100 ng/μL for 48 h; Oral gavage: 100 mg/kg for 6 weeks Sensitized cancer cells to oxaliplatin and 5-fluorouracil…”
BackgroundGrape (Vitis vinifera L.) Seed Oil: A Functional Food from the Winemaking Industry
Martin, M. E., Grao-Cruces, E., Millan-Linares, M. C., & Montserrat-de la Paz, S. (2020) · Foods · doi:10.3390/foods9101360 · Cited by 150
Yang, C., Zhang, Y., Lin, S., Liu, Y., & Li, W. (2021) · Aging · doi:10.18632/aging.202774 · Cited by 174
“…understanding of CRC biological and pathological basis, domestic and foreign basic studies regarding Oxaliplatin resistance have dug out a series of molecular mechanisms related to such AGING phenomenon; for instance, activation of the ABC transporters and supermethylation of the CpG island [5–7].”
Vazhappilly, C. G., Amararathna, M., Cyril, A. C., Linger, R. S., Matar, R., Merheb, M. M., Ramadan, W. S. H., Radhakrishnan, R., & Rupasinghe, H. P. V. (2021) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2021.108623 · Cited by 107
Sharma, P., Shimura, T., Banwait, J. K., & Goel, A. (2020) · Carcinogenesis · doi:10.1093/carcin/bgaa090 · Cited by 96
“The 5FU-resistant clones from both HCT116 and SW480 cells (HCT116 5FUR and SW480 5FUR) were established by continuous culturing of cells with increasing dose of the chemotherapeutic drug for >9 months, as described previously (27,28).”
BackgroundSelf-citation
Metadata
- Authors
- Ravindranathan, P., Pasham, D., & Goel, A.
- Affiliations
- Baylor University Medical Center (US)
- Corresponding author
- Goel, Ajay
- ORCID
- Goel, Ajay
- Venue
- Carcinogenesis
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-12-29
- Volume
- 40
- Issue
- 3
- Pages
- 412-421
- ISSN
- 0143-3334 (ISSN-L)
- 1460-2180
- PMC
- PMC6514448
- OpenAlex
- W2907792329
- Cited by
- 35
- References
- 54
- Citations by year
- 2025: 5 · 2024: 5 · 2023: 3 · 2022: 7 · 2021: 6 · 2020: 6 · 2019: 3
- FWCI
- 1.41
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Carcinogenesis (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Biochemistry (medical) › Phytochemicals and Antioxidant Activities
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- oligomeric proanthocyanidins, grape seed extract, ABC transporters, multidrug resistance, chemoresistance, colorectal cancer, 5-fluorouracil, oxaliplatin, chemosensitization, cell cycle arrest, DNA double-strand breaks, p53, xenograft tumor growth
- MeSH terms
- Oxaliplatin, Animals, Antineoplastic Agents, Fluorouracil, Humans, Male, Mice, Nude, Polymers, Colorectal Neoplasms, ATP-Binding Cassette Transporters, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Proanthocyanidins, HCT116 Cells, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.